Digital repository of Slovenian research organisations

Show document
A+ | A- | Help | SLO | ENG

Title:Capecitabine in adjuvant radiochemotherapy for gastric adenocarcinoma
Authors:ID Oblak, Irena (Author)
ID Skoblar Vidmar, Marija (Author)
ID Anderluh, Franc (Author)
ID Velenik, Vaneja (Author)
ID Jeromen, Ana (Author)
ID But-Hadžić, Jasna (Author)
Files:.pdf PDF - Presentation file, download (519,56 KB)
MD5: 81C786D883587160E5E0E01C94A2EB37
 
Language:English
Typology:1.01 - Original Scientific Article
Organization:Logo OI - Institute of Oncology
Abstract:Background. In patients with non-metastatic gastric cancer surgery still remains the treatment of choice. Postoperative radiochemotherapy with 5-fluorouracil and leucovorin significantly improves the treatment outcome. The oral fluoropyrimidines, such as capecitabine, mimic continuous 5-fluorouracil infusion, are at least as effective as 5-fluorouracil, and such treatment is more comfortable for the patients. Patients and methods. In the period from October 2006 to December 2009, 101 patients with gastric cancer in stages Ib-IIIc were treated with postoperative chemoradiation with capecitabine. Distal subtotal resection of the stomach was performed in 46.3%, total resection in 50.5% and multivisceral resection in 3.2% of patients. The main endpoints of this study were loco-regional control (LRC), disease-free survival (DFS), disease-specific survival (DSS) and overall survival (OS). The rates of acute side-effects were also estimated. Results. Seventy-seven percent of patients completed the treatment according to the protocol. The median followup time of all patients was 3.9 years (range: 0.4-6.3 years) and in survivors it was 4.7 years (range: 3.2-6.3 years). No death occurred due to the therapy. Acute toxicity, such as nausea and vomiting, stomatitis, diarrhoea, hand-foot syndrome and infections of grade 3 or 4, occurred in 5%, 1%, 2%, 8.9% and 18.8% of patients, respectively. On the close-out date 63.4% patients were still alive and with no signs of the disease. The 4-years follow-up survey showed that LRC, DFS, DSS and OS were 95.5%, 69.2%, 70.7%, and 66.2%, respectively. Higher pN-stage and splenectomy were found to be independent prognostic factors for all four types of survival and perineural invasion and lower treatment intensity for DFS, DSS and OS.
Keywords:gastric cancer, adjuvant therapy, radiochemotherapy
Publication status:Published
Publication version:Version of Record
Publication date:01.06.2014
Publisher:Association of Radiology and Oncology
Year of publishing:2014
Number of pages:str. 189-196
Numbering:Vol. 48, no. 2
Source:Ljubljana
PID:20.500.12556/DiRROS-18658 New window
UDC:616.3
ISSN on article:1318-2099
DOI:10.2478/raon-2013-0065 New window
COBISS.SI-ID:1617531 New window
Copyright:by Authors
Publication date in DiRROS:11.04.2024
Views:79
Downloads:14
Metadata:XML RDF-CHPDL DC-XML DC-RDF
:
Copy citation
  
Share:Bookmark and Share


Hover the mouse pointer over a document title to show the abstract or click on the title to get all document metadata.

Record is a part of a journal

Title:Radiology and oncology
Shortened title:Radiol. oncol.
Publisher:Slovenian Medical Society - Section of Radiology, Croatian Medical Association - Croatian Society of Radiology
ISSN:1318-2099
COBISS.SI-ID:32649472 New window

Secondary language

Language:Slovenian
Keywords:rak želodca, adjuvantno zdravljenje, radiokemoterapija


Back